Diagnosis and management of lipodystrophy: a practical update

References

• Garg A. Clinical review: lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96(11), 3313–3325 (2011). • A review of the classification, clinical features and molecular basis of lipodystrophies.
   Google Scholar
• Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J. Hum. Genet. 59(1), 16–23 (2013). • Useful review including a description of normal adipocyte differentiation and regulation, and the underlying mechanisms responsible for the pathophysiology of lipodystrophy syndromes.
   Google Scholar
• Strickland LR, Guo F, Lok K, Garvey WT. Type 2 diabetes with partial lipodystrophy of the limbs: a new lipodystrophy phenotype. Diabetes Care 36(8), 2247–2253 (2013).
   Google Scholar
• Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 26(6), 1819–1824 (2003).
   Google Scholar
• Knebel B, Kotzka J, Lehr S et al. A mutation in the c-fos gene associated with congenital generalized lipodystrophy. Orphanet. J. Rare Dis. 8, 119 (2013).
   Google Scholar
• Handelsman Y, Oral EA, Bloomgarden ZT et al. The clinical approach to the detection of lipodystrophy – an AACE consensus statement. Endocr. Pract. 19(1), 107–116 (2013). •• Recent consensus on the clinical diagnosis of lipodystrophy with useful clinical photographs to help increase diagnosis rates.
   Google Scholar
• Berardinelli W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J. Clin. Endocrinol. Metab. 14(2), 193–204 (1954).
   Google Scholar
• Seip M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr. 48, 555–574 (1959).
   Google Scholar
• Brunzell JD, Shankle SW, Bethune JE. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann. Intern. Med. 69(3), 501–516 (1968).
   Google Scholar
• Lee IH, Chen HL, Jeng YM, Cheng MT, Tsao LY, Chang MH. Congenital generalized lipodystrophy in a 4­month­old infant. J. Formos. Med. Assoc. 100(9), 623–627 (2001).
   Google Scholar
• Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl. 413, 2–28 (1996).
   Google Scholar
• Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am. J. Cardiol. 112(7), 1019–1024 (2013).
   Google Scholar
• Savage DB, Semple RK, Clatworthy MR et al. Complement abnormalities in acquired lipodystrophy revisited. J. Clin. Endocrinol. Metab. 94(1), 10–16 (2009).
   Google Scholar
• Bredella MA, Ghomi RH, Thomas BJ et al. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring) 18(11), 2227–2233 (2010).
   Google Scholar
• Vigouroux C, Magre J, Vantyghem MC et al. Lamin A/C gene: sex­determined expression of mutations in Dunnigan­ type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes 49(11), 1958–1962 (2000).
   Google Scholar
• Vantyghem MC, Pigny P, Maurage CA et al. Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. J. Clin. Endocrinol. Metab. 89(11), 5337–5346 (2004).
   Google Scholar
• Sissons JG, West RJ, Fallows J et al. The complement abnormalities of lipodystrophy. N. Engl. J. Med. 294(9), 461–465 (1976).
   Google Scholar
• Shen LY, Edmonson MB, Williams GP, Gottam CC, Hinshaw MA, Teng JM. Lipoatrophic panniculitis: case report and review of the literature. Arch. Dermatol. 146(8), 877–881 (2010).
   Google Scholar
• Badri T, Ben Hmida M, Benmously­Mlika R et al. Focal lipodystrophy without metabolic disorders in adult dermatomyositis. Int. J. Dermatol. 52(11), 1422–1424 (2013).
   Google Scholar
• Yiannias JA, DiCaudo DJ, Maskin E. Peripheral T­cell lymphoma presenting as lipoatrophy and nodules. Int. J. Dermatol. 45(12), 1415–1419 (2006).
   Google Scholar
• Zannou DM, Denoeud L, Lacombe K et al. Incidence of lipodystrophy and metabolic disorders in patients starting non­nucleoside reverse transcriptase inhibitors in Benin. Antivir. Ther. 14(3), 371–380 (2009).
   Google Scholar
• Domingo P, Estrada V, Lopez­Aldeguer J, Villaroya F, Martinez E. Fat redistribution syndromes associated with HIV­1 infection and combination antiretroviral therapy. AIDS Rev. 14(2), 112–123 (2012). • Useful review of haart–HIV-associated lipodystrophy.
   Google Scholar
• Savage DB, Murgatroyd PR, Chatterjee VK, O’Rahilly S. Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy. J. Clin. Endocrinol. Metab. 90(3), 1446–1452 (2005). • Study showing metabolic effects of a high-fat meal in patients with lipodystrophy compared with healthy control subjects.
   Google Scholar
• Taleban S, Carew HT, Dichek HL et al. Energy balance in congenital generalized lipodystrophy type I. Metabolism 57(8), 1155–1161 (2008).
   Google Scholar
• Aotani D, Ebihara K, Sawamoto N et al. Functional magnetic resonance imaging ana­lysis of food­related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J. Clin. Endocrinol. Metab. 97(10), 3663–3671 (2012). • Recent study examining appetite changes with leptin therapy, using functional MRI.
   Google Scholar
• McDuffie JR, Riggs PA, Calis KA et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J. Clin. Endocrinol. Metab. 89(9), 4258–4263 (2004).
   Google Scholar
• Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long­term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54(7), 1994–2002 (2005).
   Google Scholar
• Marais AD. Dietary lipid modification for mild and severe dyslipidaemias. Proc. Nutr. Soc. 72(3), 337–341 (2013).
   Google Scholar
• Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of Type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54(10), 2506–2514 (2011). •• Recent pilot study showing that type 2 diabetes can be reversed with low a low-calorie liquid diet, proof-of-concept that dietary restriction alone can be an effective treatment for insulin resistance.
   Google Scholar
• Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care 36(4), 1047–1055 (2013).
   Google Scholar
• Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with Type 2 diabetes. Diabetes 54(3), 603–608 (2005).
   Google Scholar
• Biro SM, Olson DL, Garren MJ, Gould JC. Diabetes remission and glycemic response to pre­bariatric surgery diet. J. Surg. Res. 185(1), 1–5 (2013).
   Google Scholar
• Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it? An operation proves to be the most effective therapy for adult­onset diabetes mellitus. Ann. Surg. 222(3), 339–350; discussion 350–332 (1995). •• Important paper illustrating that bariatric surgery can be effective as a treatment for type 2 diabetes.
   Google Scholar
• Chandarana K, Batterham RL. Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nat. Med. 18(5), 668–669 (2012).
   Google Scholar
• Neff KJ, le Roux CW. Bariatric surgery: a best practice article. J. Clin. Pathol. 66(2), 90–98 (2013).
   Google Scholar
• NICE. Obesity. Guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE clinical guideline 43. NICE, London, UK (2006).
   Google Scholar
• Lee WJ, Chong K, Chen CY et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index <35 kg/m2. Obes. Surg. 21(7), 889–895 (2011).
   Google Scholar
• Li Q, Chen L, Yang Z et al. Metabolic effects of bariatric surgery in Type 2 diabetic patients with body mass index < 35 kg/m2. Diabetes Obes. Metab. 14(3), 262–270 (2012).
   Google Scholar
• McGrath NM, Krishna G. Gastric bypass for insulin resistance due to lipodystrophy. Obes. Surg. 16(11), 1542–1544 (2006).
   Google Scholar
• Utzschneider KM, Trence DL. Effectiveness of gastric bypass surgery in a patient with familial partial lipodystrophy. Diabetes Care 29(6), 1380–1382 (2006).
   Google Scholar
• Ciudin A, Baena­Fustegueras JA, Fort JM, Encabo G, Mesa J, Lecube A. Successful treatment for the Dunnigan­type familial partial lipodystrophy with Roux­en­Y gastric bypass. Clin. Endocrinol. (Oxf.) 75(3), 403–404 (2011). • Case report illustrating the effectiveness of bariatric surgery in a patient with familial partial lipodystrophy.
   Google Scholar
• Chapman WH, Cunningham E, Pories WJ. Bariatric surgery and diabetes: access denied. Diabetes Technol. Ther. 15(Suppl. 1), S83–S87 (2013).
   Google Scholar
• O’Hagan C, De Vito G, Boreham CA. Exercise prescription in the treatment of Type 2 diabetes mellitus: current practices, existing guidelines and future directions. Sports Med. 43(1), 39–49 (2013).
   Google Scholar
• Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Short­term exercise training improves body composition and hyperlipidaemia in HIV­positive individuals with lipodystrophy. AIDS 15(15), 2049–2051 (2001).
   Google Scholar
• Henry CJ. Basal metabolic rate studies in humans: measurement and development of new equations. Public Health Nutr. 8(7A), 1133–1152 (2005).
   Google Scholar
• Watson LP, Raymond­Barker P, Moran C et al. An approach to quantifying abnormalities in energy expenditure and lean mass in metabolic disease. Eur. J. Clin. Nutr. 68(2), 234–240 (2013).
   Google Scholar
• Savage DB, Semple RK, Chatterjee VK, Wales JK, Ross RJ, O’Rahilly S. A clinical approach to severe insulin resistance. Endocr. Dev. 11 122–132 (2007).
   Google Scholar
• Whitfield­Brown L, Hamer O, Ellahi B, Burden S, Durrington P. An investigation to determine the nutritional adequacy and individuals experience of a very low fat diet used to treat type V hypertriglyceridaemia. J. Hum. Nutr. Diet 22(3), 232–238 (2009).
   Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425–432 (1994).
   Google Scholar
• Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 269(5223), 546–549 (1995).
   Google Scholar
• Halaas JL, Gajiwala KS, Maffei M et al. Weight­reducing effects of the plasma protein encoded by the obese gene. Science 269(5223), 543–546 (1995).
   Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004).
   Google Scholar
• Moon HS, Dalamaga M, Kim SY et al. Leptin’s role in lipodystrophic and nonlipodystrophic insulin­resistant and diabetic individuals. Endocr. Rev. 34(3), 377–412 (2013).
   Google Scholar
• Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341(12), 879–884 (1999).
   Google Scholar
• Chan JL, Lutz K, Cochran E et al. Clinical effects of long­ term metreleptin treatment in patients with lipodystrophy. Endocr. Pract. 17(6), 922–932 (2011). • Results of clinical trial showing the effectiveness of metreleptin therapy over at last 3 years in patients with lipodystrophy.
   Google Scholar
• Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 91(7), 2605–2611 (2006).
   Google Scholar
• Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long­term efficacy of leptin replacement in patients with Dunnigan­type familial partial lipodystrophy. Metabolism 56(4), 508–516 (2007).
   Google Scholar
• Oral EA, Simha V, Ruiz E et al. Leptin­replacement therapy for lipodystrophy. N. Engl. J. Med. 376, 570–578 (2002).
   Google Scholar
• Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53(1), 27–35 (2010).
   Google Scholar
• Simha V, Subramanyam L, Szczepaniak L et al. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J. Clin. Endocrinol. Metab. 97(3), 785–792 (2012).
   Google Scholar
• Safar Zadeh E, Lungu AO, Cochran EK et al. The liver diseases of lipodystrophy: the long­term effect of leptin treatment. J. Hepatol. 59(1), 131–137 (2013).
   Google Scholar
• Moran SA, Patten N, Young JR et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53(4), 513–519 (2004).
   Google Scholar
• Petersen KF, Oral EA, Dufour S et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109(10), 1345–1350 (2002).
   Google Scholar
• Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty­acid oxidation by activating AMP­activated protein kinase. Nature 415(6869), 339–343 (2002).
   Google Scholar
• Wolsk E, Mygind H, Grondahl TS, Pedersen BK, van Hall G. The role of leptin in human lipid and glucose metabolism: the effects of acute recombinant human leptin infusion in young healthy males. Am. J. Clin. Nutr. 1533–1544 (2011).
   Google Scholar
• Javor ED, Ghany MG, Cochran EK et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41(4), 753–760 (2005).
   Google Scholar
• Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon­like peptide­1 receptor agonists on weight loss: systematic review and meta­analyses of randomised controlled trials. BMJ 344, d7771 (2012).
   Google Scholar
• Ottney A. Glucagon­like peptide­1 receptor agonists for weight loss in adult patients without diabetes. Am. J. Health Syst. Pharm. 70(23), 2097–2103 (2013).
   Google Scholar
• Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R. Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc. Health Risk Manag. 8, 621–629 (2012).
   Google Scholar
• Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF. Exenatide, a glucagon­like peptide­1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb. Vasc. Biol. 32(6), 1513–1519 (2012).
   Google Scholar
• Oriot P, Hermans MP, Selvais P, Buysschaert M, de la Tribonniere X. Exenatide improves weight loss insulin sensitivity and beta­cell function following administration to a Type 2 diabetic HIV patient on antiretroviral therapy. Ann. Endocrinol. (Paris) 72(3), 244–246 (2011).
   Google Scholar
• Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1­based therapies and risk of hospitalization for acute pancreatitis in Type 2 diabetes mellitus: a population­based matched case­control study. JAMA Intern. Med. 73(7), 534–539 (2013).
   Google Scholar
• Mannucci E, Dicembrini I, Rotella F, Rotella CM. Orlistat and sibutramine beyond weight loss. Nutr. Metab. Cardiovasc. Dis. 18(5), 342–348 (2008).
   Google Scholar
• Harrison SA, Fecht W, Brunt EM, Neuschwander­Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49(1), 80–86 (2009).
   Google Scholar
• Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284(4), 472–477 (2000).
   Google Scholar
• Effect of intensive blood­glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131), 854–865 (1998).
   Google Scholar
• Rojas LB, Gomes MB. Metformin: an old but still the best treatment for Type 2 diabetes. Diabetol. Metab. Syndr. 5(1), 6 (2013).
   Google Scholar
• Shyangdan D, Clar C, Ghouri N et al. Insulin sensitisers in the treatment of non­alcoholic fatty liver disease: a systematic review. Health Technol. Assess. 15(38), 1–110 (2011).
   Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493), 1279–1289 (2005).
   Google Scholar
• Sheth SH, Larson RJ. The efficacy and safety of insulin­ sensitizing drugs in HIV­associated lipodystrophy syndrome: a meta­ana­lysis of randomized trials. BMC Infect. Dis. 10, 183 (2010).
   Google Scholar
• Luedtke A, Boschmann M, Colpe C et al. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series. Horm. Metab. Res. 44(4), 306–311 (2012).
   Google Scholar
• Moreau F, Boullu­Sanchis S, Vigouroux C et al. Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report. Diabetes Metab. 33(5), 385–389 (2007).
   Google Scholar
• Collet­Gaudillat C, Billon­Bancel A, Beressi JP. Long­ term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. Diabetes Metab. 35(2), 151–154 (2009).
   Google Scholar
• Savage DB, Tan GD, Acerini CL et al. Human metabolic syndrome resulting from dominant­negative mutations in the nuclear receptor peroxisome proliferator­activated receptor­ gamma. Diabetes 52(4), 910–917 (2003).
   Google Scholar
• Reutrakul S, Wroblewski K, Brown RL. Clinical use of U­500 regular insulin: review and meta­ana­lysis. J. Diabetes Sci. Technol. 6(2), 412–420 (2012). • Excellent recent review of the use of humulin-R U500 insulin in clinical practice.
   Google Scholar
• Cochran EK, Valentine V, Samaan KH, Corey IB, Jackson JA. Practice tips and tools for the successful use of U­500 regular human insulin: the diabetes educator is key. Diabetes Educ. 40(2), 153–165 (2014).
   Google Scholar
• Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U­500 insulin: why, when and how to use in clinical practice. Diabetes Metab. Res. Rev. 23(4), 265–268 (2007).
   Google Scholar
• Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes. Metab. doi:10.1111/dom.12219 (2013) (Epub ahead of print).
   Google Scholar
• Korsatko S, Deller S, Koehler G et al. A comparison of the steady­state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra­long­acting insulin degludec. Clin Drug Investig. 33(7), 515–521 (2013).
   Google Scholar
• Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra­longacting basal insulin, versus insulin glargine in basal­bolus treatment with mealtime insulin aspart in Type 2 diabetes (BEGIN Basal­Bolus Type 2): a Phase 3, randomised, open­label, treat­to­target non­inferiority trial. Lancet 379(9825), 1498–1507 (2012).
   Google Scholar
• Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: What progress have we made? Diabetes Metab. Res. Rev. 30(2), 104–119 (2014).
   Google Scholar
• Balasubramanyam A, Coraza I, Smith EO et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of ‘heart positive’, a randomized, controlled trial. J. Clin. Endocrinol. Metab. 96(7), 2236–2247 (2011).
   Google Scholar
• Stacpoole PW, Alig J, Kilgore LL et al. Lipodystrophic diabetes mellitus. Investigations of lipoprotein metabolism and the effects of omega­3 fatty acid administration in two patients. Metabolism 37(10), 944–951 (1988).
   Google Scholar
• Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr. Opin. Lipidol. 18(4), 415–420 (2007).
   Google Scholar
• Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123(20), 2292–2333 (2011). • Comprehensive guidance on triglyceride metabolism and the causes and treatment of perturbations in triglyceride metabolism.
   Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2013.11.002 (2013) (Epub ahead of print).
   Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an ana­lysis from the JUPITER trial. Lancet 380(9841), 565–571 (2012).
   Google Scholar
• Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255–2267 (2011).
   Google Scholar
• Wierzbicki AS, Clarke RE, Viljoen A, Mikhailidis DP. Triglycerides: a case for treatment? Curr. Opin. Cardiol. 27(4), 398–404 (2012).
   Google Scholar
• Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat. Rev. Endocrinol. 7(3), 137–150 (2011).
   Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor­sparing regimens for initial HIV treatment. AIDS 23(9), 1109–1118 (2009).
   Google Scholar
• de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral­associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS ONE 8(5), e63623 (2013).
   Google Scholar
• Dhillon S. Tesamorelin: a review of its use in the management of HIV­associated lipodystrophy. Drugs 71(8), 1071–1091 (2011).
   Google Scholar
• Paruthi J, Gill N, Mantzoros CS. Adipokines in the HIV/ HAART­associated lipodystrophy syndrome. Metabolism 62(9), 1199–1205 (2013).
   Google Scholar
• Mulligan K, Khatami H, Schwarz JM et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus­associated lipoatrophy and hypoleptinemia. J. Clin. Endocrinol. Metab. 94(4), 1137–1144 (2009).
   Google Scholar
• Shuck J, Iorio ML, Hung R, Davison SP. Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus­associated facial lipodystrophy: a comparison of safety, efficacy, and long­term treatment outcomes. Plast. Reconstr. Surg. 131(3), 499–506 (2013).
   Google Scholar
• Hughes JM, Stephen C, Johnson AB, Wilson S. Breast augmentation in familial partial lipodystrophy: a case report. J. Plast. Reconstr. Aesthet. Surg. 64(5), e121–e124 (2011).
   Google Scholar
• Calderoni DR, Ramos TM, de Castro JR, Kharmandayan P. Surgical management of phenotypic alterations related to the Dunnigan variety of familial partial lipodystrophy. J. Plast. Reconstr. Aesthet. Surg. 1248–1250 (2011). • Useful summary and description of cosmetic surgery approaches in patients with familial partial lipodystrophy type 2.
   Google Scholar
• Lapalorcia LM, Podda S, Campiglio G, Cordellini M. Labia majora labioplasty in HIV­related vaginal lipodystrophy: technique description and literature review. Aesthetic Plast. Surg. 37(4), 711–714 (2013).
   Google Scholar
• Ion L, Raveendran SS. Open neck lipectomy for patients with HIV­related cervical lipohypertrophy. Aesthetic Plast. Surg. 35(6), 953–959 (2011).
   Google Scholar
• Sharma D, Bitterly TJ. Buffalo hump in HIV patients: surgical management with liposuction. J. Plast. Reconstr. Aesthet. Surg. 62, 946–949 (2009).
   Google Scholar
• Klein S, Fontana L, Young VL et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350(25), 2549–2557 (2004).
   Google Scholar
• Haedersdal M, Beerwerth F, Nash JF. Laser and intense pulsed light hair removal technologies: from professional to home use. Br. J. Dermatol. 165(Suppl. 3), 31–36 (2011).
   Google Scholar
• Koulouri O, Conway GS. Management of hirsutism. BMJ 338, b847 (2009).
   Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM­Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 97, 28–38.e25 (2012).
   Google Scholar
• Lungu AO, Zadeh ES, Goodling A, Cochran E, Gorden P. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 97(2), 563–567 (2012).
   Google Scholar
• Gambineri A, Semple RK, Forlani G et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur. J. Endocrinol. 159, 347–353 (2008).
   Google Scholar
• Hermanns­Le T, Scheen A, Pierard GE. Acanthosis nigricans associated with insulin resistance: pathophysiology and management. Am. J. Clin. Dermatol. 5(3), 199–203 (2004).
   Google Scholar
• Kapoor S. Diagnosis and treatment of Acanthosis nigricans. Skinmed 8(3), 161–164 (2010).
   Google Scholar
• Hartman R, Defelice T, Tzu J, Meehan S, Sanchez M. Acanthosis nigricans in the setting of niacin therapy. Dermatol. Online J.17(10), 11 (2011).
   Google Scholar
• Barbato MT, Criado PR, Silva AK, Averbeck E, Guerine MB, Sa NB. Association of acanthosis nigricans and skin tags with insulin resistance. An. Bras. Dermatol. 87(1), 97–104 (2012).
   Google Scholar
• Constantine Samaan M. Management of pediatric and adolescent Type 2 diabetes. Int. J. Pediatr. 2013, 972034 (2013).
   Google Scholar
• Sarni RO, Souza FI, Battistini TR et al. Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed. J. Pediatr. (Rio J.) 85(4), 329–334 (2009).
   Google Scholar
• Beltrand J, Beregszaszi M, Chevenne D et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli–Seip congenital lipoatrophy. Pediatrics 120(2), e291–e296 (2007). • Describes the effectiveness of metreleptin therapy in young children with congenital generalized lipodystrophy.
   Google Scholar
• Zeitler P, Hirst K, Pyle L et al. A clinical trial to maintain glycemic control in youth with Type 2 diabetes. N. Engl. J. Med. 366(24), 2247–2256 (2012).
   Google Scholar
• Kelly AS, Metzig AM, Rudser KD et al. Exenatide as a weight­loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 20(2), 364–370 (2012).
   Google Scholar
• Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with Type 2 diabetes mellitus being treated with metformin: a randomized, placebo­ controlled, single­blind, dose­escalation, crossover study. Clin. Ther. 31(4), 806–815 (2009).
   Google Scholar
• Black JA, White B, Viner RM, Simmons RK. Bariatric surgery for obese children and adolescents: a systematic review and meta­ana­lysis. Obes. Rev. 14(8), 634–644 (2013).
   Google Scholar
• Kim RJ, Vaghani S, Zifchak LM et al. In vitro and in vivo effects of IGF­I on adiposity in HIV­associated metabolic disease: a pilot study. Arch. Med. Res. 44(5), 361–369 (2013).
   Google Scholar
• Regan FM, Williams RM, McDonald A et al. Treatment with recombinant human insulin­like growth factor (rhIGF)­I/rhIGF binding protein­3 complex improves metabolic control in subjects with severe insulin resistance. J. Clin. Endocrinol. Metab. 95(5), 2113–2122 (2010).
   Google Scholar
• Fujikura J, Hosoda K, Nakao K. Cell transplantation therapy for diabetes mellitus: endocrine pancreas and adipocyte. Endocr. J. 60(6), 697–708 (2013).
   Google Scholar